Ocugen announced that it has acquired US, European, and Japanese rights to an intranasal COVID-19 vaccine developed at Washington University in St. Louis. In September 2020, Bharat Biotech announced that it had acquired rights to rights to the Washington University intranasal COVID-19 vaccine outside of the United States, Europe, and Japan, and Bharat recently … [Read more...] about Ocugen licenses intranasal COVID-19 vaccine from Washington University in St. Louis
News
Qnovia raises $17 million for development of inhaled nicotine replacement therapy
According to Qnovia, which recently changed its name from Respira Technologies, the company has closed a $17 million Series A financing round led by Blue Ledge Capital, with the funds intended to support development of the company's RespiRx inhaled nicotine replacement therapy (NRT). The company said that it intends to submit an IND for the NRT product and anticipates … [Read more...] about Qnovia raises $17 million for development of inhaled nicotine replacement therapy
Wake Forest University School of Medicine gets Alzheimer’s Association grant for Phase 2 trial of intranasal insulin
According to Atrium Health Wake Forest Baptist, Wake Forest University School of Medicine has received a two-year $795,000 grant from the Alzheimer’s Association to support a Phase 2 trial of empagliflozin and intranasal insulin for Alzheimer's disease. The trial will be led by Wake Forest professor Suzanne Craft, who is director of the Alzheimer's Disease Research … [Read more...] about Wake Forest University School of Medicine gets Alzheimer’s Association grant for Phase 2 trial of intranasal insulin
RS BioTherapeutics raises $3 million for development of RSBT-001 inhaled cannabidiolic acid
RS BioTherapeutics, which recently announced positive results from a proof of concept study of its RSBT-001 semi-synthetic cannabidiolic acid (CBDa) in a mouse model, said that the company has raised $3 million in a Seed II funding round. The company says that it is partnered with Synthonics and Marshall University on development of a nebulized formulation of RSBT-001 … [Read more...] about RS BioTherapeutics raises $3 million for development of RSBT-001 inhaled cannabidiolic acid
Vectura gets go-ahead to build new facility for its Inhalation Centre of Excellence
According to inhalation CDMO Vectura, the company been granted planning permission to build a new £58 million, 10,000 sq m facility in Southwest England to house the company's Inhalation Centre of Excellence, with construction expected to be completed in 2025. The company said that it aims for the building on the Bristol & Bath Science Park to receive a BREEAM … [Read more...] about Vectura gets go-ahead to build new facility for its Inhalation Centre of Excellence
Recipharm joins IPAC-RS
CDMO and device maker Recipharm has joined the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) as a member, the company announced. Recipharm will be represented on the IPAC-RS Board by Head of Commercial – Advanced Delivery Systems Peter Hirst and Director of Inhalation Sciences and Product Development Lei Mao. According to … [Read more...] about Recipharm joins IPAC-RS
Health Canada approves Ryaltris nasal spray for the treatment of seasonal allergic rhinitis
According to Bausch Health and Glenmark, Health Canada has approved Ryaltris olopatadine / mometasone furoate nasal spray for the treatment of seasonal allergic rhinitis in people aged 6 and older. Bausch Health acquired the Canadian rights to Ryaltris in March 2021. Ryaltris has been approved in Australia since December 2019, in Europe since April 2021 and in the US … [Read more...] about Health Canada approves Ryaltris nasal spray for the treatment of seasonal allergic rhinitis
United Therapeutics stops Phase 3 PERFECT trial of Tyvaso inhalation solution in PH-COPD patients
On a form 8-k filed with the US Securities and Exchange Commission (SEC), United Therapeutics reported the following: "On September 20, 2022, United Therapeutics Corporation (the Company) announced the termination of the PERFECT clinical study evaluating Tyvaso (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with chronic … [Read more...] about United Therapeutics stops Phase 3 PERFECT trial of Tyvaso inhalation solution in PH-COPD patients
Nanopharm and Fluidda team up to help inhaled drug developers pursue the alternative bioequivalence pathway
OINDP development specialist Nanopharm, which was acquired by Aptar Pharma in 2019, and functional respiratory imaging (FRI) company Fluidda are teaming up to help sponsors of ANDAs for inhaled drugs for asthma and COPD avoid the need for clinical end-point studies by pursuing the alternative bioequivalence pathway. Sponsors of 505(b)(2) NDAs for inhaled drugs and … [Read more...] about Nanopharm and Fluidda team up to help inhaled drug developers pursue the alternative bioequivalence pathway
MedPharm to provide development services for Mosanna’s MOS-118 potassium channel blocker nasal spray for sleep apnea
CDMO MedPharm has announced that it will provide formulation and delivery development services for Swiss startup Mosanna Therapeutics' MOS-118 potassium channel blocker, with the goal of advancing a nasal spray formulation into clinical development for the treatment of metabolic obstructive sleep apnea (MOSA). Mosanna was formed recently to develop MOS-118 (formerly … [Read more...] about MedPharm to provide development services for Mosanna’s MOS-118 potassium channel blocker nasal spray for sleep apnea